SubHero Banner

Verzenio® (abemaciclib) – New indication, expanded indication

October 13, 2021 - Eli Lilly announced the FDA approval of Verzenio (abemaciclib), in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score ≥ 20% as determined by an FDA approved test.

Download PDF